The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Cyclo Therapeutics's share price is $1.40.
Cyclo Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.07. Hence, Cyclo Therapeutics's PS Ratio for today is 20.90.
The historical rank and industry rank for Cyclo Therapeutics's PS Ratio or its related term are showing as below:
CYTH'
s PS Ratio Range Over the Past 10 Years
Min: 1.75 Med: 19.38 Max: 87.5
Current: 20.9
During the past 13 years, Cyclo Therapeutics's highest PS Ratio was 87.50. The lowest was 1.75. And the median was 19.38.
CYTH's PS Ratio is ranked worse than 94.31% of 1001
companies
in the Drug Manufacturers industry
Industry Median: 2.2
vs CYTH: 20.90
Cyclo Therapeutics Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Cyclo Therapeutics was -59.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -51.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -44.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -31.90% per year.
During the past 13 years, Cyclo Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 24.10% per year. The lowest was -51.10% per year. And the median was -17.20% per year.
Back to Basics: PS Ratio
Cyclo Therapeutics PS Ratio Historical Data
The historical data trend for Cyclo Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cyclo Therapeutics's PS Ratio
For the Drug Manufacturers - Specialty & Generic subindustry, Cyclo Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclo Therapeutics's PS Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cyclo Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cyclo Therapeutics's PS Ratio falls into.
Cyclo Therapeutics PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Cyclo Therapeutics's Share Price of today is $1.40. Cyclo Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.07.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Cyclo Therapeutics (NAS:CYTH) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Cyclo Therapeutics PS Ratio Related Terms
Thank you for viewing the detailed overview of Cyclo Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Cyclo Therapeutics (Cyclo Therapeutics) Business Description
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CYTH has been successfully added to your 